Zydus acquires rights to market MonoFerric injection in India, Nepal

Zydus Lifesciences Ltd on Friday said it has acquired rights to market MonoFerric (iron isomaltoside) injection, used to treat iron deficiency in adult patients, in India and Nepal from Denmark-based Pharmacosmos A/S.

MonoFerric is indicated for the treatment of iron deficiency in adult patients when oral iron preparations are ineffective or cannot be used or where there is a clinical need to deliver iron rapidly, the company said in a regulatory filing.


Comments are closed.